On April 14, 2022, in consultation with the Nominating and Corporate Governance Committee (the Committee) of the Board of Directors (the Board) of Voyager Therapeutics, Inc., Mark Levin and Steven Paul, M.D. each requested not to be nominated for re-election to the Board when his current term expires at the Company's 2022 annual meeting of stockholders. Each director cited a desire to reduce his professional commitments and the number of boards of public companies on which he serves. The Committee has engaged a search firm to identify candidates to fill the anticipated vacancies to be created by the departures of Mr. Levin and Dr. Paul following the Company's 2022 annual meeting.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.51 USD | -3.30% |
|
+1.07% | +0.83% |
Jun. 13 | Voyager Therapeutics Names Nathan Jorgensen as Finance Chief | MT |
Jun. 13 | Voyager Therapeutics, Inc. Appoints Nathan Jorgensen as Chief Financial Officer, Effective July 8, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.83% | 479M | |
+40.80% | 55.66B | |
-8.05% | 38.98B | |
+35.79% | 38.8B | |
-8.98% | 27.32B | |
+10.69% | 26.29B | |
-16.21% | 20.25B | |
+31.00% | 12.76B | |
+28.51% | 12.18B | |
-1.67% | 12.12B |
- Stock Market
- Equities
- VYGR Stock
- News Voyager Therapeutics, Inc.
- Mark Levin and Steven Paul Requests Voyager Therapeutics Not to Nominate for Re-Election to the Board